Avalon Pharmaceuticals

Avalon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of cancer therapeutics using its proprietary AvalonRx technology in the United States. The company's lead product candidate, AVN944, is an inosine monophosphate dehydrogenase (IMPDH) inhibitor currently in Phase IIa clinical development for the treatment of hematological malignancies and solid tumors.